Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy.

ABSTRACT:

Background

Prescribing anti-programmed death-1 (PD-1) immunotherapy for advanced melanoma is currently not restricted by any biomarker assessment. Determination of programmed death-ligand-1 (PD-L1)-expression status is technically challenging and is not mandatory, because negative tumours also achieve therapeutic responses. However, reproducible biomarkers predictive of a response to anti-PD-1 therapy could contribute to improving therapeutic decision-making.

Methods

This retrospective study on 70 metastatic melanoma patients was undertaken to evaluate the relationships between clinical, histological, immunohistochemical and/or molecular criteria, and the 6-month objective response rate.

Results

Better objective response rates were associated with metachronous metasta

SUBMITTER: Dupuis F 

PROVIDER: S-EPMC6048096 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature